Evidence map›Paper›PMID 36071048›Full record

ArticleBlood cancer journal2022

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

Carmelo Gurnari, Alfonso Piciocchi, Stefano Soddu, Fabrizio Bonanni, Emilia Scalzulli, Pasquale Niscola, Ambra Di Veroli, Anna Lina Piccioni, Monica Piedimonte, Gianluca Maiorana and 15 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Molecular and therapeutic frontiers in anemia therapy.The Journal of clinical investigation · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.Current treatment options in oncology · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Carmelo GurnariDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.ORCID 0000-0001-6829-5544
Alfonso PiciocchiItalian Group for Adult Hematologic Diseases (GIMEMA) Foundation, Rome, Italy.
Stefano SodduItalian Group for Adult Hematologic Diseases (GIMEMA) Foundation, Rome, Italy.
Fabrizio BonanniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Emilia ScalzulliGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Pasquale NiscolaGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Ambra Di VeroliGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Anna Lina PiccioniGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Monica PiedimonteGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Gianluca MaioranaGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Prassede SalutariHematology, Pescara Hospital, Pescara, Italy.
Laura CicconiGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.ORCID 0000-0001-5642-3051
Michelina SantopietroGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Svitlana GumenyukGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Chiara SarloGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Susanna FenuGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Agostino TafuriGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Roberto LatagliataGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Luana FianchiGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Marianna CriscuoloGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Luca MaurilloDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Francesco BuccisanoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Massimo BrecciaGROM-L (Gruppo Romano-Laziale MDS), Rome, Italy.ORCID 0000-0003-1163-6162
Maria Teresa VosoDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. voso@med.uniroma2.it.ORCID 0000-0002-6164-4761

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myelodysplastic SyndromesHumansLenalidomideThalidomideLenalidomideThalidomide

Identifiers

PMID36071048
PMCPMC9452671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.